Clinical Trial Update: A Phase II Clinical Trial of Chiglitazar for NASH [Phase 2]

View source ↗

Summary

A Phase II trial of chiglitazar for nonalcoholic steatohepatitis has completed. The study was sponsored by Chipscreen Biosciences, Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Chiglitazar (Chiglitazar)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: NASH | Phase 2 | Status: COMPLETED